A Prospective, Multicenter, Randomized, Study of the Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Nov 2021 According to a jCyte media release, the application of these key findings will help the company maximize the probability of success of the pivotal Phase 3 RP trial program without significantly limiting the potential pool of study candidates, since most RP patients have greater than 20 degrees of central visual field and a central subfield mean thickness of greater than 130 microns.
15 Nov 2021 According to a jCyte media release, results were presented at AAO 2021.
15 Nov 2021 Results presented in a jCyte Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com